Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Flannery, Tim Cooley, Kevin Krenzke

Premium

The American College of Medical Genetics and Genomics has appointed David Flannery to medical director. Flannery is board-certified in both clinical genetics and pediatrics, and he joins ACMG from the Medical College of Georgia where he served in a variety of clinical, academic, and medical staff leadership positions since 1984, including professor of pediatrics and chief of the genetics division. He is a founding fellow of ACMG and he is currently the ACMG representative to the American Medical Association's CPT Advisory Committee. He has also served as a member of the Southeast Regional Newborn Screening & Genetics Collaboratives.


MolecularHealth has added two new members to its US executive team: Tim Cooley and Kevin Krenzke.

Cooley will be senior VP of IT at MolecularHealth. He previously spent 15 years at Eli Lilly, where he held various positions, including director of IT. Krenzke will be senior VP of finance at MolecularHealth. He joins the firm after holding leadership roles at McKesson Specialty Health and US Oncology.

The new additions to the MolecularHealth team come as the company is readying to launch in the first quarter its TreatmentMap next-gen sequencing-based tests to guide cancer treatment.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.